Malaria chemoprevention after discharge lowers death in anemic children: NEJM

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2020-12-02 22:30 GMT | Update On 2020-12-03 07:30 GMT

Africa: Three months of malaria chemoprevention with dihydroartemisinin–piperaquine helps in preventing deaths or readmission after hospital discharge in children (younger than 3 years) hospitalized for severe anemia, suggests a recent study. The study, published in the New England Journal of Medicine, was conducted in areas with intense malaria transmission.

In areas of Africa where malaria is endemic, severe anemia leads to substantial increase in childhood mortality and is a leading cause of hospital admission. Such children have a high risk of readmission and death within 6 months after discharge. The strategies aimed to reduce the risk during this postdischarge period may be substantial importance for public health. But no prevention strategy specifically addresses this period. Considering this, the researchers conducted a multicenter, two-group, randomized, placebo-controlled trial in nine hospitals in Kenya and Uganda. Their aim was to determine whether 3 months of malaria chemoprevention could reduce morbidity and mortality after hospital discharge in children younger than 5 years of age who had been admitted with severe anemia.

The researchers hypothesized that administration of malaria prophylaxis during a limited period after transfusion would give sufficient time for bone marrow recovery resulting in a more sustained hematologic recovery.

All children received standard in-hospital care for severe anemia and a 3-day course of artemether–lumefantrine at discharge. Two weeks after discharge, 1049 children were randomly assigned to receive dihydroartemisinin–piperaquine (chemoprevention group; n=524) or placebo (n=525), administered as 3-day courses at 2, 6, and 10 weeks after discharge. Children were followed for 26 weeks after discharge.

The primary outcome was one or more hospital readmissions for any reason or death from the time of randomization to 6 months after discharge.

Key findings of the study include:

From week 3 through week 26, a total of 184 events of readmission or death occurred in the chemoprevention group and 316 occurred in the placebo group (hazard ratio, 0.65).
The lower incidence of readmission or death in the chemoprevention group than in the placebo group was restricted to the intervention period (week 3 through week 14) (hazard ratio, 0.30) and was not sustained after that time (week 15 through week 26) (hazard ratio, 1.13).
No serious adverse events were attributed to dihydroartemisinin–piperaquine.

"In areas with intense malaria transmission, 3 months of postdischarge malaria chemoprevention with monthly dihydroartemisinin–piperaquine in children who had recently received treatment for severe anemia prevented more deaths or readmissions for any reason after discharge than placebo," concluded the authors.

The study, "Malaria Chemoprevention in the Postdischarge Management of Severe Anemia," is published in the New England Journal of Medicine.

DOI: 10.1056/NEJMoa2002820

Article Source : NEJM

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Medha Baranwal

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Malaria chemoprevention after discharge lowers death in anemic children: NEJM

Similar News

Child Depression Fluctuations may trigger Parent Depression not vice versa: JAMA

FDA Expands Approval of Vonvendi for von Willebrand Disease, Including Pediatric Use

WHO Expands 2025 Essential Medicines List, Adding Life-Saving Cancer and Diabetes Treatments

Children with Type 1 Diabetes Face Increased Risk of Acute Leukemia, Study Finds

X-rays Effectively Clear Most Pediatric Cervical Spine Injuries, 10-Year Trauma Center Study Finds

Influenza-Associated Acute Necrotizing Encephalopathy rare but Severe in Children, reports JAMA

Urinary NGAL Emerges as a Reliable Biomarker in Nephrotic Syndrome: Study Finds

WHO and UN Launch Implementation Toolkits to Improve Quality Antenatal and Postnatal Care Worldwide